These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22072960)

  • 1. Assessing predicted HIV-1 replicative capacity in a clinical setting.
    Kouyos RD; von Wyl V; Hinkley T; Petropoulos CJ; Haddad M; Whitcomb JM; Böni J; Yerly S; Cellerai C; Klimkait T; Günthard HF; Bonhoeffer S;
    PLoS Pathog; 2011 Nov; 7(11):e1002321. PubMed ID: 22072960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Only slight impact of predicted replicative capacity for therapy response prediction.
    Weisser H; Altmann A; Sierra S; Incardona F; Struck D; Sönnerborg A; Kaiser R; Zazzi M; Tschochner M; Walter H; Lengauer T
    PLoS One; 2010 Feb; 5(2):e9044. PubMed ID: 20140263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection.
    Barbour JD; Hecht FM; Wrin T; Segal MR; Ramstead CA; Liegler TJ; Busch MP; Petropoulos CJ; Hellmann NS; Kahn JO; Grant RM
    J Infect Dis; 2004 Jul; 190(2):251-6. PubMed ID: 15216458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV type 1 polymerase gene polymorphisms are associated with phenotypic differences in replication capacity and disease progression.
    Ng OT; Laeyendecker O; Redd AD; Munshaw S; Grabowski MK; Paquet AC; Evans MC; Haddad M; Huang W; Robb ML; Reynolds SJ; Gray RH; Wawer MJ; Serwadda D; Eshleman SH; Quinn TC
    J Infect Dis; 2014 Jan; 209(1):66-73. PubMed ID: 23922373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic testing for HIV-1 drug resistance using dried blood samples.
    Lira R; Valdez-Salazar H; Vazquez-Rosales G; Rojas-Montes O; Ruiz-Tachiquin M; Torres-Ibarra R; Cano-Dominguez C; Maldonado-Rodríguez A; Gomez A; Muñoz O; Alvarez-Muñoz MT
    Arch Virol; 2010 Jul; 155(7):1117-25. PubMed ID: 20496089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordant response to HAART: reduction of viremia and replicative capacity of HIV strains in patients after genotype guided change of therapy.
    Sarmati L; Montano M; Dori L; Buonomini AR; D'Ettorre G; Vullo V; Andreoni M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):95-8. PubMed ID: 15646070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.
    Ojwach DBA; MacMillan D; Reddy T; Novitsky V; Brumme ZL; Brockman MA; Ndung'u T; Mann JK
    J Virol; 2018 Oct; 92(19):. PubMed ID: 29997209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults.
    Barbour JD; Wrin T; Grant RM; Martin JN; Segal MR; Petropoulos CJ; Deeks SG
    J Virol; 2002 Nov; 76(21):11104-12. PubMed ID: 12368352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel.
    Wegner SA; Brodine SK; Mascola JR; Tasker SA; Shaffer RA; Starkey MJ; Barile A; Martin GJ; Aronson N; Emmons WW; Stephan K; Bloor S; Vingerhoets J; Hertogs K; Larder B
    AIDS; 2000 May; 14(8):1009-15. PubMed ID: 10853983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.
    Sakai K; Chikata T; Brumme ZL; Brumme CJ; Gatanaga H; Oka S; Takiguchi M
    Retrovirology; 2015 Nov; 12():98. PubMed ID: 26585907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.
    Theys K; Deforche K; Vercauteren J; Libin P; van de Vijver DA; Albert J; Asjö B; Balotta C; Bruckova M; Camacho RJ; Clotet B; Coughlan S; Grossman Z; Hamouda O; Horban A; Korn K; Kostrikis LG; Kücherer C; Nielsen C; Paraskevis D; Poljak M; Puchhammer-Stockl E; Riva C; Ruiz L; Liitsola K; Schmit JC; Schuurman R; Sönnerborg A; Stanekova D; Stanojevic M; Struck D; Van Laethem K; Wensing AM; Boucher CA; Vandamme AM;
    Retrovirology; 2012 Oct; 9():81. PubMed ID: 23031662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in Cameroon.
    Ragupathy V; Zhao J; Wood O; Tang S; Lee S; Nyambi P; Hewlett I
    Virol J; 2011 Apr; 8():185. PubMed ID: 21513545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 drug resistance in newly infected individuals.
    Boden D; Hurley A; Zhang L; Cao Y; Guo Y; Jones E; Tsay J; Ip J; Farthing C; Limoli K; Parkin N; Markowitz M
    JAMA; 1999 Sep 22-29; 282(12):1135-41. PubMed ID: 10501116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of primary drug resistance among recently HIV-1 infected adults.
    Barbour JD; Hecht FM; Wrin T; Liegler TJ; Ramstead CA; Busch MP; Segal MR; Petropoulos CJ; Grant RM
    AIDS; 2004 Aug; 18(12):1683-9. PubMed ID: 15280779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of antiretroviral resistance on viral fitness.
    Nijhuis M; Deeks S; Boucher C
    Curr Opin Infect Dis; 2001 Feb; 14(1):23-8. PubMed ID: 11979111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.